Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
95 stopped studies mapped to Primitive Neuroectodermal Tumor and descendants · 88% state a reason
Over the 95 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06858501 | Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk… | Phase 2 | withdrawn | Mar 5, 2025 | Children's Oncology Group | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT04539366 | Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children,… | Phase 1 | suspended | Sep 7, 2020 | National Cancer Institute (NCI) | Other - review of safety data | Safety / toxicity |
| NCT04751383 | Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in… | Phase 1 | terminated | Feb 12, 2021 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT05130255 | GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 | Phase 1 | terminated | Nov 23, 2021 | Y-mAbs Therapeutics | Decision by Sponsor | Other (stated, no rule matched) |
| NCT04500548 | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in… | Phase 1 | withdrawn | Aug 5, 2020 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT02780128 | Next Generation Personalized Neuroblastoma Therapy(NEPENTHE) | Phase 1 | terminated | May 23, 2016 | Yael P Mosse | The goals of Part 1 (molecular screening) were met, but lack of therapies to match molecular… | Other (stated, no rule matched) |
| NCT05429502 | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and… | Phase 1 | terminated | Jun 23, 2022 | Novartis Pharmaceuticals | Study halted early due to high toxicity risk (from BHLRM model) in combo treatment and inability to… | Safety / toxicity |
| NCT04023331 | 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients… | Phase 1 / Phase 2 | terminated | Jul 17, 2019 | Clarity Pharmaceuticals Ltd | Sponsor decision | Sponsor / business decision |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | Phase 1 | terminated | Jan 23, 2020 | Actuate Therapeutics Inc. | The decision to conclude study was made to optimize the clinical study design and protocol to… | Safety / toxicity |
| NCT04530487 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or… | Phase 2 | terminated | Aug 28, 2020 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT02100891 | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid…(STIR) | Phase 2 | terminated | Apr 1, 2014 | Monica Thakar | 15 patients enrolled out of planned 20, terminated due to slow enrollment at end of study | Enrollment / accrual |
| NCT04239040 | GVAX Plus Checkpoint Blockade in Neuroblastoma | Phase 1 | terminated | Jan 23, 2020 | Dana-Farber Cancer Institute | Manufacturing issues | Drug supply |
| NCT06233903 | 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic… | Phase 2 | withdrawn | Jan 31, 2024 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | Logistical considerations | Other (stated, no rule matched) |
| NCT06308575 | A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory… | Phase 2 | withdrawn | Mar 13, 2024 | M.D. Anderson Cancer Center | PI Request--No Patient Accrual | Enrollment / accrual |
| NCT04029688 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of… | Phase 1 / Phase 2 | terminated | Jul 23, 2019 | Hoffmann-La Roche | Study was terminated by the sponsor based on insufficient tolerability and efficacy to proceed… | Efficacy / futility |
| NCT04521946 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade… | Phase 1 | withdrawn | Aug 21, 2020 | M.D. Anderson Cancer Center | No participants enrolled. | Enrollment / accrual |
| NCT04753658 | Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib | — | terminated | Feb 15, 2021 | Pfizer | The study was prematurely discontinued due to operational implementation challenges and… | Other (stated, no rule matched) |
| NCT06182410 | Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for… | Phase 2 | withdrawn | Dec 26, 2023 | University of California, San Francisco | Industry sponsor decision | Sponsor / business decision |
| NCT01483820 | Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma | Phase 1 / Phase 2 | terminated | Dec 1, 2011 | Giselle Sholler | Lack of enrollment | Enrollment / accrual |
| NCT01505608 | Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed… | Phase 1 / Phase 2 | terminated | Jan 6, 2012 | Giselle Sholler | Lack of Enrollment | Enrollment / accrual |
| NCT02630043 | Trial of Tolcapone With Oxaliplatin for Neuroblastoma | Phase 1 | terminated | Dec 15, 2015 | Giselle Sholler | Lack of study enrollment | Enrollment / accrual |
| NCT06335745 | PediCARE Health Equity Intervention in High-Risk Neuroblastoma | N/A | withdrawn | Mar 28, 2024 | Dana-Farber Cancer Institute | Study halted prematurely, prior to enrollment of first participant | Enrollment / accrual |
| NCT02110563 | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors,… | Phase 1 | terminated | Apr 10, 2014 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Sponsor Decision | Sponsor / business decision |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | Phase 2 | terminated | Dec 8, 2015 | University of Virginia | Poor enrollment | Enrollment / accrual |
| NCT03275402 | 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous… | Phase 2 / Phase 3 | terminated | Sep 7, 2017 | Y-mAbs Therapeutics | Corporate business decision. Not due to safety or efficacy concerns. | Safety / toxicity |
| NCT00089245 | Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or… | Phase 1 | terminated | Aug 5, 2004 | Y-mAbs Therapeutics | Corporate business decision. No safety or efficacy concerns. | Safety / toxicity |
| NCT03458728 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | Phase 1 / Phase 2 | terminated | Mar 8, 2018 | Bayer | no anticipated benefit over available standard therapies | Other (stated, no rule matched) |
| NCT03406273 | Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in… | N/A | withdrawn | Jan 23, 2018 | Giselle Sholler | No enrollment to study, study closed | Enrollment / accrual |
| NCT03860207 | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in… | Phase 1 / Phase 2 | terminated | Mar 1, 2019 | Y-mAbs Therapeutics | study terminated due to business priorities | Sponsor / business decision |
| NCT02536183 | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric… | Phase 1 | terminated | Aug 31, 2015 | AeRang Kim | low accrual | Enrollment / accrual |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With… | Phase 1 / Phase 2 | terminated | Nov 10, 2008 | City of Hope Medical Center | Terminated early due a shift in resources after lackluster performance of the drug. | Other (stated, no rule matched) |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in…(PIVOT IO 020) | Phase 1 / Phase 2 | terminated | Jan 29, 2021 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT02641782 | NB2013-HR German (GPOH) / Dutch (DCOG) Trial(NB2013-HR) | Phase 2 | terminated | Dec 29, 2015 | University of Cologne | Antibody supply was discontinued by United Therapeutics Corporation. | Drug supply |
| NCT03209869 | Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded… | Phase 1 | withdrawn | Jul 6, 2017 | University of Wisconsin, Madison | resources limited due to COVID-19 | COVID-19 / pandemic |
| NCT04909515 | Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin… | Phase 2 | withdrawn | Jun 1, 2021 | Y-mAbs Therapeutics | Study terminated due to business priorities | Sponsor / business decision |
| NCT02163356 | Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant…(SPOC2013-001) | Phase 1 | terminated | Jun 13, 2014 | South Plains Oncology Consortium | drug supply | Drug supply |
| NCT01583842 | 124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients… | Early Phase 1 | terminated | Apr 24, 2012 | Miguel Pampaloni | Funding | Funding |
| NCT02580136 | Esthesioneuroblastoma: Outcomes After Treatment(ENB) | — | withdrawn | Oct 20, 2015 | Ricardo L. Carrau, MD | Lack of accrual | Enrollment / accrual |
| NCT00202930 | Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma | Phase 2 | terminated | Sep 20, 2005 | Jean M. Tersak, M.D. | Closed early due to low accrual. | Enrollment / accrual |
| NCT01987596 | Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After… | Phase 3 | terminated | Nov 19, 2013 | Barbara Ann Karmanos Cancer Institute | not stated | Not stated |
| NCT00698009 | Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory… | Phase 2 | terminated | Jun 16, 2008 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT01916187 | Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children… | Phase 1 | withdrawn | Aug 5, 2013 | NCIC Clinical Trials Group | drug company withdrew support following re-examination of benefit-risk assessment for the… | Sponsor / business decision |
| NCT00428272 | HGS-ETR2 to Treat Children With Solid Tumors | Phase 1 | terminated | Jan 29, 2007 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01117155 | A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas | — | withdrawn | May 5, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01251913 | A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration… | — | terminated | Dec 2, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01747876 | Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and… | Phase 1 | terminated | Dec 12, 2012 | Novartis Pharmaceuticals | Lack of efficacy caused enrollment to be stopped at the end of dose escalation | Efficacy / futility |
| NCT00651716 | T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem… | — | terminated | Apr 3, 2008 | Vanderbilt-Ingram Cancer Center | Funding unavailable | Funding |
| NCT01183884 | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater… | Phase 2 | terminated | Aug 18, 2010 | Memorial Sloan Kettering Cancer Center | Low participant accrual | Enrollment / accrual |
| NCT02177773 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies(DOTA-TOC) | Phase 1 / Phase 2 | terminated | Jun 30, 2014 | University of California, San Francisco | FDA approved agent for this indication during enrollment | Enrollment / accrual |
| NCT02689336 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory… | Phase 2 | withdrawn | Feb 23, 2016 | Washington University School of Medicine | Could not recruit any participants | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 13 days agoSource updated Sep 16, 2026source: clinicaltrials